TUESDAY, Dec. 13, 2022 (HealthDay News) -- The U.S. Preventive Services Task Force (USPSTF) recommends preexposure prophylaxis (PrEP) for reducing the risk for HIV infection among individuals at increased risk for HIV acquisition. This recommendation forms the basis of a draft recommendation statement published online Dec. 13.
Roger Chou, M.D., from the Pacific Northwest Evidence-Based Practice Center at the Oregon Health & Science University in Portland, and colleagues conducted a systematic review on the effects of PrEP on the risk for HIV acquisition, mortality, harms, and other clinical outcomes. The researchers found that in 11 trials involving populations at higher risk for acquiring HIV infection, oral PrEP was associated with a reduced risk for HIV infection versus placebo or no PrEP (relative risk, 0.46). The effects were consistent across HIV risk categories and for tenofovir disoproxil fumarate (TDF) plus emtricitabine or TDF alone. A strong association was seen between higher adherence and greater efficacy (relative risks, 0.27, 0.51, and 0.93, for adherence ≥70 percent, >40 to <70 percent, and ≤40 percent, respectively). The risk for serious adverse events, sexually transmitted diseases, or adverse pregnancy-related outcomes did not differ for PrEP versus placebo/no PrEP.
Based on these findings, the USPSTF recommends prescribing PrEP to adolescents and adults who are at increased risk for HIV acquisition to reduce the risk for acquiring HIV infection (A recommendation).
The draft evidence review and recommendation statement have been posted for public comment. Comments can be submitted from Dec. 13, 2022, through Jan. 17, 2023.
Draft Recommendation Statement
Comment on Recommendation Statement
- On World AIDS Day, White House Announces Plan to End Epidemic by 2030 ›
- Long-Acting Cabotegravir Not Necessarily Cost-Effective for PrEP ›
- Black, Hispanic/Latino MSM Less Likely to Have HIV Diagnosis ›
- Long-Acting Injectable Preferred for HIV Preexposure Prophylaxis - Consumer Health News | HealthDay ›
- Link Found Between Maternal HIV Status and Inflammation in Pregnancy - Consumer Health News | HealthDay ›
- PEPFAR Has Scaled Up HIV ART to About 20 Million Persons Since 2004 - Consumer Health News | HealthDay ›
- Weight Gain, Raised BP Risk Seen for HIV Patients Switching to Dolutegravir - Consumer Health News | HealthDay ›